GlobalFoundries Inc. Ordinary Shares vs TransMedics Group Inc — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $48.03 (market cap $27.51B), while TransMedics Group Inc trades at $78.47 (market cap $2.74B). The key difference: GlobalFoundries Inc. Ordinary Shares is far larger — about 10× TransMedics Group Inc's market cap, and GlobalFoundries Inc. Ordinary Shares pays a 0.97% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and TransMedics Group Inc for 24 Days on average.
| GFS | TMDX | |
|---|---|---|
Market Cap | $27.51B | $2.74B |
Volume | 10,416,572 | 949,331 |
Sector | Technology | Health |
52-Week High | $89.96 | $150.42 |
52-Week Low | $32.24 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $26.80B | $3.13B |
Dividend Yield | 0.97% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.
Read more on GFS →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →